Last reviewed · How we verify
Clofarabine, ara-C — Competitive Intelligence Brief
phase 2
Nucleoside analog and cytosine analog
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Clofarabine, ara-C (Clofarabine, ara-C) — Hannover Medical School. Clofarabine is a nucleoside analog that interferes with DNA synthesis, while ara-C is a cytosine analog that also interferes with DNA synthesis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Clofarabine, ara-C TARGET | Clofarabine, ara-C | Hannover Medical School | phase 2 | Nucleoside analog and cytosine analog |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Nucleoside analog and cytosine analog class)
- Hannover Medical School · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Clofarabine, ara-C CI watch — RSS
- Clofarabine, ara-C CI watch — Atom
- Clofarabine, ara-C CI watch — JSON
- Clofarabine, ara-C alone — RSS
- Whole Nucleoside analog and cytosine analog class — RSS
Cite this brief
Drug Landscape (2026). Clofarabine, ara-C — Competitive Intelligence Brief. https://druglandscape.com/ci/clofarabine-ara-c. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing